Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s ...